

Immix Biopharma

Improved NEXICART-2 data; runway extends

Immix Biopharma has announced an update from its ongoing US-based NEXICART-2 study testing NXC-201 in relapsed/refractory amyloid light chain amyloidosis (r/r ALA), alongside a sizeable equity financing to support continued development activities. The latest clinical update showed that all four measurable residual disease (MRD)-negative patients previously reported at ASH 2025 have now converted to complete response (CR), increasing the CR rate to 95% (19/20 patients) in the first 20 evaluable participants. Importantly, all CRs were reached within one year following dosing and no relapses have been observed to date among patients who achieved CR. We view this as an encouraging progression from the prior dataset, which showed a 75% CR rate (15/20 patients), with management previously indicating that the MRD-negative patients could deepen into CR over time. Safety findings were reported as consistent with prior disclosures, including no reported neurotoxicity and manageable cytokine release syndrome. Separately, Immix announced the closing of a \$150m underwritten offering of common stock and pre-funded warrants. Management estimates that its cash resources, with this new financing, should provide operational headroom to mid-2028.

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/24	0.0	(18.6)	(0.66)	0.00	N/A	N/A
12/25	0.0	(27.0)	(0.82)	0.00	N/A	N/A
12/26e	0.0	(31.5)	(0.57)	0.00	N/A	N/A
12/27e	38,495.4	(4.5)	(0.08)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

The latest NEXICART-2 update builds directly on the interim dataset presented at ASH 2025, where NXC-201 demonstrated a 75% CR rate across the first 20 treated patients. At the time, management highlighted that four of the five non-CR patients were MRD negative. The new [update](#) confirms that all four of these patients have now converted to CR, increasing the overall CR rate to 95% (19/20 patients). In our view, this represents an important development, as it shows continued deepening of responses over time. Management also disclosed that all subsequently enrolled patients with available MRD data had achieved MRD negativity at one month, providing additional encouragement.

NEXICART-2 completed patient enrolment (n=45) in March 2026. Immix has communicated that the next update is on track for September 2026, and stated that this will be followed by one-year follow-up data by end-March 2027. The latter is expected to drive Biologics License Application (BLA) submission and commercial launch, a slight adjustment from prior guidance of BLA submission within 2026. We also highlight Immix's plans to initiate a multi-centre, randomised Phase III trial in newly diagnosed ALA patients (in contrast to the r/r setting) in H127, reflecting growing confidence in the candidate's efficacy profile, in our view. We await further details on this front before adjusting our longer-term assumptions.

Separately, Immix announced the closing of a \$150m underwritten public offering consisting of common stock and pre-funded warrants. The net [proceeds](#) (c \$141m after deducting offering expenses) are expected to support ongoing clinical development activities, working capital and general corporate purposes. Importantly, with an extended cash runway to mid-2028, the company has greater financial flexibility ahead of key upcoming clinical milestones and inflection points.

Clinical and funding update


Healthcare

26 May 2026

Price **\$8.94**
Market cap **\$486m**

Net cash at 31 March 2026 \$90.6m
 Shares in issue 54.4m
 Free float 60.0%
 Code IMMX
 Primary exchange NASDAQ
 Secondary exchange N/A

Share price performance



Business description

Immix Biopharma is a clinical-stage biopharma company developing personalised therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset being evaluated for relapsed/refractory amyloid light chain amyloidosis with plans to expand to autoimmune indications. A Phase I/II trial, NEXICART-2, is ongoing in the US, with top-line results expected from Q326.

Analysts

Arron Aatkar, PhD +44 (0)20 3077 5700
 Jyoti Prakash, CFA +44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

Immix Biopharma is a research client of Edison Investment Research Limited

General disclaimer and copyright

This report has been commissioned by Immix Biopharma and prepared and issued by Edison, in consideration of a fee payable by Immix Biopharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.